# A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer

> **NCT05103826** · PHASE1 · TERMINATED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 3 (actual)

## Conditions studied

- ER+ / HER2- Advanced Breast Cancer

## Interventions

- **DRUG:** SHR6390、Famitinib

## Key facts

- **NCT ID:** NCT05103826
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-25
- **Primary completion:** 2023-06-15
- **Final completion:** 2023-06-15
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Sponsor R \& D Strategy Adjustment
- **Last updated:** 2023-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05103826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05103826, "A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05103826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*